Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 41
Filtrar
Mais filtros

País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Med Intensiva ; 46(2): 81-89, 2022 Feb.
Artigo em Espanhol | MEDLINE | ID: mdl-34545260

RESUMO

The COVID-19 pandemic has led to the admission of a high number of patients to the ICU, generally due to severe respiratory failure. Since the appearance of the first cases of SARS-CoV-2 infection, at the end of 2019, in China, a huge number of treatment recommendations for this entity have been published, not always supported by sufficient scientific evidence or with methodological rigor necessary. Thanks to the efforts of different groups of researchers, we currently have the results of clinical trials, and other types of studies, of higher quality. We consider it necessary to create a document that includes recommendations that collect this evidence regarding the diagnosis and treatment of COVID-19, but also aspects that other guidelines have not considered and that we consider essential in the management of critical patients with COVID-19. For this, a drafting committee has been created, made up of members of the SEMICYUC Working Groups more directly related to different specific aspects of the management of these patients.

3.
Med Intensiva ; 39(8): 459-66, 2015 Nov.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-25843698

RESUMO

OBJECTIVE: To assess how antibiotic administration delay and inadequacy influence survival in septic shock patients. DESIGN: A prospective, observational cohort study was carried out between September 2005 and September 2010. SCOPE: Patients admitted to the ICU of a third level hospital. PATIENTS: A total of 342 septic shock patients INTERVENTIONS: None VARIABLES OF INTEREST: The time to antibiotic administration (difference between septic shock presentation and first administered dose of antibiotic) and its adequacy (in vitro susceptibility testing of isolated pathogens) were determined. RESULTS: ICU and hospital mortality were 26.4% and 33.5%, respectively. The median delay to administration of the first antibiotic dose was 1.7h. Deceased patients received antibiotics significantly later than survivors (1.3±14.5h vs. 5.8±18.02h; P=.001). Percentage drug inadequacy was 12%. Those patients who received inadequate antibiotics had significantly higher mortality rates (33.8% vs. 51.2%; P=.03). The coexistence of treatment delay and inadequacy was associated to lower survival rates. CONCLUSIONS: Both antibiotic administration delay and inadequacy exert deleterious effects upon the survival of septic shock patients, independently of their characteristics or severity.


Assuntos
Antibacterianos/uso terapêutico , Choque Séptico/tratamento farmacológico , Tempo para o Tratamento , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/administração & dosagem , Infecções Comunitárias Adquiridas/tratamento farmacológico , Infecções Comunitárias Adquiridas/mortalidade , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/mortalidade , Esquema de Medicação , Resistência Microbiana a Medicamentos , Feminino , Mortalidade Hospitalar , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Índice de Gravidade de Doença , Choque Séptico/mortalidade , Espanha/epidemiologia , Centros de Atenção Terciária/estatística & dados numéricos
4.
Med Intensiva (Engl Ed) ; 46(2): 81-89, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-34903475

RESUMO

The COVID-19 pandemic has led to the admission of a high number of patients to the ICU, generally due to severe respiratory failure. Since the appearance of the first cases of SARS-CoV-2 infection, at the end of 2019, in China, a huge number of treatment recommendations for this entity have been published, not always supported by sufficient scientific evidence or with methodological rigor necessary. Thanks to the efforts of different groups of researchers, we currently have the results of clinical trials, and other types of studies, of higher quality. We consider it necessary to create a document that includes recommendations that collect this evidence regarding the diagnosis and treatment of COVID-19, but also aspects that other guidelines have not considered and that we consider essential in the management of critical patients with COVID-19. For this, a drafting committee has been created, made up of members of the SEMICYUC Working Groups more directly related to different specific aspects of the management of these patients.


Assuntos
COVID-19 , Estado Terminal/terapia , Humanos , Unidades de Terapia Intensiva , Pandemias , SARS-CoV-2
5.
Nutr Hosp ; 22(1): 124-5, 2007.
Artigo em Espanhol | MEDLINE | ID: mdl-17260541

RESUMO

Metformin is a biguanide extensively used in the treatment of type II diabetes mellitus. Between the nocive effects of the metformin emphasizes tha lactic acidosis because of its low frecuency but potential severity. The diagnosis of the poisoning due to metformin is based on the coexistence of lactic acidosis and one or more of the risk factors. The development of lactic acidosis in metformin poisoning is associated to a range of 50-80% of mortality.


Assuntos
Acidose Láctica/induzido quimicamente , Hipoglicemiantes/intoxicação , Metformina/intoxicação , Idoso , Humanos , Masculino , Índice de Gravidade de Doença
6.
An Med Interna ; 24(1): 35-7, 2007 Jan.
Artigo em Espanhol | MEDLINE | ID: mdl-17373868

RESUMO

We present the case of a 59 year old woman with no previous clinical history of disease who was admitted in our ICU due to respiratory failure and hemodynamic instability. She was found to have purulent pericarditis due to Streptococcus pneumoniae, complicated by massive pericardial effusion and pleural empyema. A pericardial tap was performed unsuccessfully and finally pericardial effusion was evacuated by surgical drainage. Pleural empyema was also evacuated. She received antibiotic treatment and recovered with normalisation of heart function.


Assuntos
Empiema Pleural/microbiologia , Pericardite/microbiologia , Infecções Pneumocócicas/complicações , Streptococcus pneumoniae/isolamento & purificação , Antibacterianos/uso terapêutico , Empiema Pleural/diagnóstico por imagem , Empiema Pleural/terapia , Feminino , Humanos , Pessoa de Meia-Idade , Pericardiectomia , Pericardite/diagnóstico por imagem , Pericardite/cirurgia , Infecções Pneumocócicas/diagnóstico , Infecções Pneumocócicas/cirurgia , Radiografia , Resultado do Tratamento , Ultrassonografia
19.
Med Intensiva ; 34(7): 446-52, 2010 Oct.
Artigo em Espanhol | MEDLINE | ID: mdl-20381201

RESUMO

OBJECTIVE: To validate the "Risk Quantification of Early Outcome After Lung Transplantation" (RQLT) scale in a cohort of lung transplantation patients. DESIGN: The parameters included in the RQLT scale were recorded prospectively. PATIENT: A total of 74 lung transplant patients in the University Hospital Marquis of Valdecilla (Santander) were analyzed between September 2004 and March 2008. MAIN VARIABLES OF INTEREST: This was the association of the score on the RQLT scale with mortality at 30 days and prolonged ICU stay. The dependent variable of mortality at 30 days was adjustment of scale using the logistic regression model. Diagnostic efficacy was evaluated using the ROC curve and calibration of the system on the sample with the Hosmer and Lemeshow goodness of fit test. RESULTS: The 30-day mortality in lung transplant patients increases significantly as the RQLT score increases, with an odds ratio (OR) of 2.20 (1.24-3.93) for each point increase on the RQLT scale. The area under the ROC curve for 30-day mortality was 0.79 (0.68-0.88; P=0.01). The Hosmer and Lemeshow goodness of fit test described a value p=0.58. CONCLUSIONS: The RQLT scale is a useful tool as an indicator of 30-day mortality in transplant patients.


Assuntos
Transplante de Pulmão/mortalidade , Medição de Risco , Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
20.
Med. intensiva (Madr., Ed. impr.) ; 39(8): 459-466, nov. 2015. tab, graf
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-144787

RESUMO

OBJETIVO: Evaluar cómo influye el retraso en la administración de la primera dosis de antibiótico y la inadecuación de la pauta seleccionada en la supervivencia de los pacientes en shock séptico. DISEÑO: Estudio prospectivo de cohortes observacional realizado entre septiembre de 2005 y septiembre de 2010. ÁMBITO: Pacientes hospitalizados en la UCI de un hospital de tercer nivel. PACIENTES: Trescientos cuarenta y dos pacientes con cuadro de shock séptico. INTERVENCIONES: Ninguna. Variables de interés principales: Se determinó el tiempo hasta la administración del antibiótico (diferencia entre la presentación del shock séptico y la primera dosis de antibiótico) y la adecuación del mismo (susceptibilidad in vitro de los microorganismos aislados). RESULTADOS: La mortalidad en UCI fue del 26,4% y a nivel hospitalario del 33,5%. La mediana de retraso en la administración de la primera dosis de tratamiento antibiótico fue de 1,7 h. Los pacientes fallecidos recibieron el antibiótico significativamente más tarde (1,3 ± 14,5 h frente a 5,8 ± 18,02; p = 0,001) que los supervivientes. El porcentaje de inadecuación del tratamiento antibiótico fue del 12%. Los pacientes tratados inadecuadamente presentaron cifras de mortalidad hospitalaria significativamente más altas (33,8% frente a 51,2%; p = 0,03) respecto a los que recibieron una pauta antibiótica adecuada. La coexistencia de retraso e inadecuación en el tratamiento antibiótico se asoció a una menor supervivencia de los pacientes. CONCLUSIONES: Tanto el retraso como la inadecuación del tratamiento antibiótico tienen efectos negativos sobre la supervivencia de los pacientes en shock séptico independientemente de las características de estos o de su estado de gravedad


OBJECTIVE: To assess how antibiotic administration delay and inadequacy influence survival in septic shock patients. DESIGN: A prospective, observational cohort study was carried out between September 2005 and September 2010. SCOPE: Patients admitted to the ICU of a third level hospital. PATIENTS: A total of 342 septic shock patients Interventions: None Variables of interest: The time to antibiotic administration (difference between septic shock presentation and first administered dose of antibiotic) and its adequacy (in vitro susceptibility testing of isolated pathogens) were determined. RESULTS: ICU and hospital mortality were 26.4% and 33.5%, respectively. The median delay to administration of the first antibiotic dose was 1.7 h. Deceased patients received antibiotics significantly later than survivors (1.3 ± 14.5 h vs. 5.8 ± 18.02 h; P = .001). Percentage drug inadequacy was 12%. Those patients who received inadequate antibiotics had significantly higher mortality rates (33.8% vs. 51.2%; P = .03). The coexistence of treatment delay and inadequacy was associated to lower survival rates. CONCLUSIONS: Both antibiotic administration delay and inadequacy exert deleterious effects upon the survival of septic shock patients, independently of their characteristics or severity


Assuntos
Humanos , Antibacterianos/administração & dosagem , Sepse/tratamento farmacológico , Choque Séptico/tratamento farmacológico , Tempo para o Tratamento/estatística & dados numéricos , Diagnóstico Precoce , Análise de Sobrevida , Resultado do Tratamento , Estudos Prospectivos , Conduta do Tratamento Medicamentoso , Testes de Sensibilidade Microbiana
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA